GlassScriptPhysician profile
Sara Sokolowski
NPI 1346827987
$4,462.15
in general payments reported to CMS, 2019-2025
22 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $871 · 2023: $494 · 2024: $651 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,877.35 | 2025 | Rapiblyk |
| Novartis Pharmaceuticals Corporation | $673.91 | 2021-2025 | |
| Boston Scientific Corporation | $320.04 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply, Mylux Patient Kit With Mobile Device |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.33 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $182.85 | 2022-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $167.61 | 2024 | Arcalyst |
| Medtronic, INC. | $159.06 | 2021-2025 | Mycarelink |
| Cvrx, INC. | $136.77 | 2022-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $117.10 | 2022 | |
| Astellas Pharma US INC | $111.69 | 2022 | |
| Biotronik INC. | $98.42 | 2023 | Biomonitor, Acticor 7 Vr-T Dx |
| Kiniksa Pharmaceuticals, LTD. | $73.68 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $67.91 | 2022-2025 | Verquvo, Capvaxive |
| Cleerly, INC. | $50.33 | 2025 | Cleerly Ischemia, Cleerly Labs |
| E.R. Squibb & Sons, L.L.C. | $32.42 | 2022-2023 | Camzyos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.27 | 2023-2024 | Wegovy |
| Edwards Lifesciences Corporation | $27.96 | 2023 | |
| Bridgebio Pharma, INC. | $17.90 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $17.51 | 2023 | |
| Scpharmaceuticals INC. | $15.43 | 2024 | |
| Lilly USA, LLC | $15.04 | 2024 | Zepbound |
| Amgen INC. | $13.57 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sokolowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.